{{Rsnum
|rsid=9397456
|Gene=ESR1
|Chromosome=6
|position=151926017
|Orientation=plus
|GMAF=0.2622
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ESR1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 37.5 | 62.5
| HCB | 24.4 | 51.1 | 24.4
| JPT | 20.5 | 54.5 | 25.0
| YRI | 0.0 | 12.7 | 87.3
| ASW | 0.0 | 0.0 | 0.0
| CHB | 24.4 | 51.1 | 24.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9397456
|Name_s=
|Gene_s=ESR1
|Feature=
|Evidence=PubMed ID:18854778
|Annotation=In a Swedish population, but not in a French population, the A allele of this SNP was associated with increased fasting plasma glucose levels. This SNP was not associated with type 2 diabetes in either study population.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162360222
}}

{{PMID Auto
|PMID=18053221
|Title=Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis--a cohort study.
|OA=1
}}

{{PMID Auto
|PMID=18305958
|Title=Comprehensive evaluation of the estrogen receptor alpha gene reveals further evidence for association with type 2 diabetes enriched for nephropathy in an African American population.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9397456
|overall_frequency_n=94
|overall_frequency_d=128
|overall_frequency=0.734375
|n_genomes=49
|n_genomes_annotated=0
|n_haplomes=86
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}